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Abstract 
 
Thrombocytopenia is common among individuals infected with HIV, with a wide range of possible 
causes. It often necessitates the performance of a bone marrow investigation in order to assess 
megakaryocyte activity and to exclude the presence of bone marrow infiltration. Unfortunately, 
meaningful interpretation of the bone marrow findings is often hampered by the frequent co-
existence of multiple potential pathogenic processes. For example, megakaryocyte numbers are 
often well preserved (even in the presence of marrow infiltration), but show a degree of dysplasia, 
(suggesting that ineffective megakaryopoiesis is contributing to the thrombocytopenia). In addition, 
processes associated with peripheral platelet consumption (such as immune-mediated platelet 
destruction or disseminated intravascular coagulation) are also common, and the mechanism causing 
thrombocytopenia is therefore often obscure. Because this mechanism is of clinical interest, (in that 
it guides the selection of the most appropriate therapy), a functional test of megakaryocyte activity 
would be of potential value. 
 The IPF is a platelet parameter measured on the Sysmex XE-5000 haematology analyzer, which 
quantifies the number of reticulated platelets, and has been shown to be a good reflector of 
underlying bone marrow megakaryocyte activity. 
  The objectives of this study were therefore to measure the IPF level in HIV-positive patients with 
thrombocytopenia who had undergone a bone marrow investigation, and to correlate the IPF with 
the bone marrow morphology findings and other clinical variables of interest (including the CD4 
count, the HIV viral load and the presence of opportunistic infections or malignancies). The IPF was 
also assessed as a tool to predict the short term platelet count response to the therapy initiated by 
the attending clinician. 
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 78 patients were enrolled, of whom 38 (49%) had mycobacterial infection, 12 (15%) had ITP/TTP and 
eight (10.3%) had a malignancy. CD4 counts were available in 70 patients, of whom 63 (90%) had 
AIDS. Thirty seven patients (47%) were found to have an IPF level greater than 7.7% , with an overall 
population mean IPF level of 9.5%.   
A strong relationship was identified between the IPF and the platelet count, with 81% of patients 
with grade four thrombocytopenia having an IPF level greater than 7.7% (mean IPF=14%), as 
compared to only 8% of grade one thrombocytopenia (mean IPF=6%). 67% of patients with 
hypocellular or extensively infiltrated marrow had a low IPF (≤ 7.7%)(mean=7%), as compared to only 
25% of patients with ITP/TTP (mean=14.8%). A higher proportion of patients with low viral load levels 
had a low IPF as compared to those with higher viral loads, possibly due to the apparent sparing of 
patients with low viral loads from grade four thrombocytopenia.  In contrast, the presence of a 
significant degree of megakaryocyte dysplasia, a very low CD4 count or the presence of 
mycobacterial infection did not affect the IPF distribution, suggesting that the underlying mechanism 
causing thrombocytopenia in these subgroups was heterogeneous.  
An IPF level greater than 10% predicted a partial platelet count response (as defined as an 
improvement by greater than 50% of the baseline platelet count to a minimum level of 20x10^9/l), 
with a specificity of 81% and a positive predictive value of 79%, while an IPF level less than 6% had a 
specificity of 89% and a positive predictive value of 70% for a complete failure to show a platelet 
count response to the therapy instituted. 
Limitations of the IPF illuminated in this study include a loss of reliability in any circumstance in which 
the platelet count as measured by optical fluorescence may be in question, and includes disorders 
associated with profound red cell fragmentation and some malignancies.  
 v 
 
The cause of thrombocytopenia is concluded to be very heterogeneous in thrombocytopenic patients 
with AIDS, even among patients with a unifying diagnosis (such as mycobacterial infection). The IPF is 
therefore a useful tool to assist the morphologist in interpreting the bone marrow findings in this 
clinical setting, as well as in predicting the short term platelet count response to therapy.   
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Chapter 1:  
1.0 Introduction  
 
1.1 An overview of HIV infection in South Africa 
 
The human immunodeficiency virus (HIV) is a retrovirus which affects human immunity, resulting in 
the acquired immunodeficiency syndrome (AIDS) [1]. It infects in excess of 33 million people world-
wide [2], with more than five million affected individuals residing in South Africa [3]. The CD4 
molecule expressed by CD4 T-cells, monocytes and macrophages is the primary cellular receptor for 
HIV, and infection of these cells by the virus is associated with a slow, progressive drop in the CD4 T-
cell count with an associated decline in cell mediated immunity [1].  When the CD4 count drops 
below a level of 200x10^6/l, the infected individual is rendered significantly immunocompromised, 
and is then classified as having immunological AIDS [1]. Some individuals may present with AIDS-
related pathology with a relatively preserved CD4 count (i.e. a CD4 count>200x10^6/l), in which case 
they are classified as having clinical AIDS. HIV/AIDS may manifest as a wide range of clinical entities 
affecting virtually every organ system as a result of either opportunistic infection or malignancy, or a 
direct viral effect [1]. In South Africa, Tuberculosis (TB) is a particularly important infection in HIV-
infected individuals, with 60% of patients with TB, in whom the HIV status is known, being HIV 
positive [4]. This is due to the extremely high incidence of TB in the population as a whole (which is in 
excess of 950/100 000 population [5] compared to a global incidence rate of 140/100 000 population 
[6]). Malignancies have an increased incidence in this setting for many reasons, including the effects 
of chronic antigenic stimulation and a propensity to infection with potentially oncogenic viruses (such 
as Kaposi’s sarcoma herpes virus (KSHV) or Epstein-Barr virus (EBV)) [7]. High grade lymphomas are 
among the most common malignancies encountered,  with the incidence of Hodgkin’s lymphoma, 
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diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma  being eight times, 60-200 times, and  
1000 times more common than in the background population respectively [7].  
The gold standard treatment for AIDS is a combination of anti-retroviral (ARV) drugs, including both 
nucleoside reverse transcriptase inhibitors (NRTIs) (such as zidovudine, lamivudine and stavudine) 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (such as nevirapine and efavirenz) [8]. 
However, statistics from 2007 showed that less than 30% of South African’s with AIDS had been 
initiated on anti-retroviral therapy [3]. 
 
1.2 A brief overview of platelet biology  
1.2.1 What are platelets?  
Platelets are small anucleate cellular structures which circulate in the peripheral blood (see Figure 
1.1). They are discoid in shape, and although anucleate, their cytoplasm contains a number of 
organelles, granules and cytoskeletal proteins. They express surface receptors for collagen, von 
Willebrand factor (vWF) and fibrinogen, which mediate platelet immobilization and aggregation at 
the site of an endothelial breach. These interactions result in the formation of a primary platelet plug, 
which physically occludes the site of injury, thus preventing significant blood loss. In addition, they 
provide a very large phospholipid surface area for the action of phospholipid dependent coagulation 
proteins, and contain many procoagulant substances within their granules. They play a critical role in 
forming a stable thrombus in the event of a vessel wall injury, and a person with an abnormally low 
platelet count (thrombocytopenia) may therefore present with a propensity to bleed [9]. 
 3 
 
 
Figure 1.1: Normal blood showing red blood cells interspersed by much smaller platelets (see 
arrows) (May-Grünwald-Giemsa stain, 50x magnification).  
 
1.2.2 A brief overview of platelet production.  
Platelets are synthesized in the bone marrow by large polyploidy cells called megakaryocytes [9]. 
These extrude cytoplasmic processes (called proplatelet processes) from their cell surfaces, which 
dissociate from the parent megakaryocyte (as proplatelets), and then subsequently fragment further 
to form mature platelets [10] (see Figure 1.2). Platelets therefore are fragments of megakaryocyte 
cytoplasm.   
 
Platelet production is controlled by a number of soluble haemopoietic growth factors, including 
thrombopoietin (TPO), interleukin (IL)-3 and IL-11. Platelets have a lifespan of between seven and ten 
days, and therefore need to be synthesized at a rate of ~1x10^11 per day  in order to maintain a  
platelet count within the normal range (between ~140-400x10^9/l in healthy individuals) [11]. 
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Figure 1.2. Platelets are formed from sequential fragmentation of cytoplasmic extensions 
(proplatelets) from the megakaryocyte surface.  
 
Bone marrow production of platelets can be up-regulated when necessary, largely through the action 
of TPO, the serum levels of which are inversely proportional to the peripheral blood platelet count 
[12]. Two important mechanisms modulate serum TPO levels. The first is dependent on the 
expression of high affinity TPO receptors (Mpl) on both platelets and megakaryocytes. When platelet 
numbers are normal, TPO binds to its receptor on platelets and is therefore functionally unavailable 
for binding to Mpl on megakaryocytes. Conversely, when platelet levels are low, available TPO is 
increased, and is able to bind it’s receptor on megakaryocytes and stimulate new platelet production 
[13]. The second mechanism at play depends upon increased TPO production in response to 
thrombocytopenia.  Although TPO is synthesized by the liver, kidney and bone marrow stromal cells, 
an increase in TPO mRNA production in the setting of thrombocytopenia occurs only in the bone 
marrow stromal cells, while TPO mRNA levels in the liver and kidney are not influenced by the 
 5 
 
platelet count [14]. One important mechanism of control of TPO production by bone marrow stromal 
cells is mediated by proteins present in the alpha granules of platelets, which if present, suppress 
TPO production [15]. TPO levels are therefore greatly influenced by the presence of mature platelets. 
The latter example also illustrates how the activity of megakaryocytes is dependent on the milieu in 
which they are located, with surrounding endothelial and stromal cells within the bone marrow 
microenvironment playing an essential role in maintaining normal megakaryopoiesis [11].  
 
1.3 An overview of thrombocytopenia 
 
Thrombocytopenia may occur as a consequence of either a failure of the bone marrow to produce 
sufficient platelets (i.e. a central defect), or of excessive consumption or loss of platelets at a rate 
which exceeds the bone marrow’s rate of platelet synthesis (i.e. a peripheral disturbance). The causes 
of thrombocytopenia are summarized in Table 1.1.  
 
1.4 Indication for a bone marrow investigation: 
 
As a general rule, if a peripheral mechanism for thrombocytopenia is evident, a bone marrow 
investigation is not usually indicated [16]. However, if a central cause for the thrombocytopenia is 
suspected or there is cause for doubt about the underlying mechanism at play, a bone marrow 
aspirate and trephine biopsy are indicated [16].  Platelet production failure is characterized by either 
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abnormal megakaryocyte morphology or a reduction in their numbers, while peripheral mechanisms 
are usually associated with increased megakaryocyte numbers. 
Table 1.1: An overview of the causes of thrombocytopenia 
Platelet production failure  Reduced platelet survival 
Hypoplastic/aplastic anaemia.  
 
Immune thrombocytopenia (ITP) 
Nutritional deficiencies 
          -Vitamin B12 
           -Folic acid 
           -Iron 
Microangiopathic haemolytic anaemia 
(MAHA) 
   - Disseminated intravascular coagulation 
(DIC) 
    - Thrombotic Thrombocytopenic Purpura 
(TTP)  
Bone marrow infiltration 
       -Malignant 
       -Infectious 
Hypersplenism  
 
Infection 
      -Secondary hypoplastic/aplastic anaemia 
       -Granuloma formation 
       - Cytokine mediated haemophagocytosis 
       -Direct viral infection of megakaryocytes 
 
Drug or toxin effect  
The Myelodysplastic Syndome (MDS)  
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1.5 Thrombocytopenia in the setting of HIV infection: 
 
Thrombocytopenia occurs with a prevalence of 3-30% in HIV infected individuals [17, 18]. It is more 
common among those with AIDS [17, 18] and may be reduced in some cases by anti-retroviral 
therapy [19]. This high prevalence occurs due to the frequent occurrence of pathologies associated 
with thrombocytopenia in this setting, including ITP [20, 21], TTP [22] and opportunistic malignancies 
(which may infiltrate the bone marrow or cause splenomegaly). Opportunistic infections are also 
highly prevalent, which may produce a myriad of effects. For instance, many viruses may cause 
hypoplastic/aplastic anaemia [23], and infectious agents can infiltrate the bone marrow (as may 
occur in miliary mycobacterial infection) or cause splenomegaly.  In addition, severe sepsis may either 
impair platelet production, (possibly as a result of cytokine mediated haemophagocytosis within the 
bone marrow [24, 25]) or enhance platelet consumption by precipitating DIC [26].  
 
HIV positive individuals are also frequently exposed to a cocktail of medications, many of which may 
suppress megakaryopoiesis, cause secondary ITP or result in ineffective haemopoiesis [27-33]. Lastly, 
platelet production is impaired in the setting of HIV as a consequence of both stromal cell 
dysfunction [34] and direct viral infection of megakaryocytes by means of CD4 molecules expressed 
on the megakaryocyte surface [35].  As a result of one or more of these influences, the bone marrow 
of HIV infected persons may show hyper- or hypocellularity, with  increased numbers of bare 
megakaryocyte nuclei (signifying increased megakaryocyte death) and morphologically dysplastic 
haemopoietic precursors, with or without evidence of bone marrow infiltration [29].  
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Using radio-isotope labeled platelets, it has been shown that immune destruction of platelets is more 
often seen in patients with higher CD4 counts, while those with more advanced HIV disease (although 
also vulnerable to immune-type thrombocytopenia) more often experience a platelet production 
defect [36]. Unfortunately, establishing the mechanism of thrombocytopenia in these patients on a 
routine basis is largely dependent on morphological assessment of the bone marrow, which is made 
difficult by the frequent finding of increased numbers of megakaryocytes with a degree of 
morphological atypia [29]. As the presence of a peripheral cause of thrombocytopenia often 
necessitates a specific therapeutic intervention, establishing the mechanism of thrombocytopenia is 
of clinical interest. 
 
1.6 Background information about the immature platelet fraction 
(IPF): 
 
Because platelets are anucleate, they are unable to synthesize new RNA after they have dissociated 
from the parent megakaryocyte. The presence of RNA-rich platelets (so-called “reticulated platelets”) 
was first demonstrated in the late 1960’s [37], and these were confirmed to be newly formed 
platelets in the mid 1990’s [38, 39]. A relationship between megakaryocytic activity and the 
percentage of reticulated platelets in the peripheral blood was first demonstrated by Kienast and 
Schmitz in 1990 [40], and has subsequently been confirmed on numerous occasions [41-43]. 
Assessment of numbers of reticulated platelets has now been automated by Sysmex, and can be 
measured as the “immature platelet fraction” (IPF) using a Sysmex XE-5000 haematology analyzer 
(Sysmex, Kobe, Japan). This parameter is measured as part of a routine full blood count, and is 
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reported as a proportion of the total optical platelet count. The test methodology entails the 
demonstration of RNA-rich platelets by means of a fluorescent RNA-binding intracellular dye, which 
are then quantified by means of flow cytometry [44] (see Figure 1.3).  
 
 
Plt count: 80x10^9/l
IPF: 3% 
Plt count: 72 x10^9/l
IPF: 34%
A B
 
Figure 1.3: Optical platelet scattergrams from thrombocytopenic individuals with low (A) and high 
(B) IPF levels respectively. Mature platelets appear as aqua dots (see orange arrows), while 
reticulated platelets are depicted as green dots (see white arrows). In addition to having higher 
fluorescence intensities as compared to mature platelets, reticulated platelets are also slightly larger.  
 
 
 
Like reticulated platelets quantified by other means, the IPF has been shown to correlate directly 
with the underlying mechanism of thrombocytopenia in a number of clinical contexts, including  ITP  
as well as chemotherapy-related thrombocytopenia [44, 45]. Of interest, an increase in the IPF has 
been shown to herald a recovery in the platelet count within approximately three days in the setting 
of marrow hypoplasia [44]. The IPF may therefore be useful in assessing the expected time for the 
platelet count to recover spontaneously in this clinical setting, therefore facilitating the selection of a 
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group of thrombocytopenic patients who may not require a platelet transfusion in the face of 
imminent recovery of the platelet count. 
 
 Data from a study conducted in Japan on 137 thrombocytopenic patients from a variety of causes 
demonstrated that the best IPF cut-off to discriminate the patients with normal/suppressed platelet 
production from those with increased platelet production is 7.7%. This cutoff value was able to 
delineate underlying megakaryopoietic activity with a sensitivity of 86.8% and a specificity of 92.6% 
[44]. In this study, the normal range assessed in 129 healthy Japanese individuals (1-10.3%; mean 
3.3%) was similar to the normal range established both in normal English subjects (1.1–6.1%, mean  
3.4%) [45], and in a population of healthy South Africans (1.1%-5.9%, mean ~3.5%) (personal 
communication, M Munster). 
 
To the author’s knowledge, there has only been one publication on reticulated platelet numbers in 
HIV positive patients to date. This study assessed the platelets of 14 thrombocytopenic HIV infected 
individuals using an alternative method to the automated IPF assessment, and showed increased 
reticulated platelet numbers in all 14 patients [46]. However, this finding should perhaps be treated 
with reserve given the large body of evidence implicating impaired platelet production as an 
important mechanism of thrombocytopenia in HIV-positive patients, particularly in light of the small 
sample size. 
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1.7 The objectives of this MMed Research Report: 
In summary, thrombocytopenia is a common finding in the setting of HIV, with many possible 
underlying mechanisms. This report aims to: 
1) Quanititate the IPF in HIV-positive thrombocytopenic patients. 
 
2) Assess for an association between the IPF and clinical variables (such as the CD4 count, 
medications, additional underlying pathology (including opportunistic infection or malignancy). 
 
3)  Assess whether there is any association between the IPF at the time of bone marrow 
investigation with the short-term behavior of the platelet count in response to the treatment 
implemented at the discretion of the treating doctor.  
 
4)  Assess the relationship between the morphological characteristics of megakaryopoiesis with 
the IPF. 
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Chapter 2:  
2.0 Materials and Methods 
2.1 Patients: 
Participants were identified through the bone marrow register in the haematology laboratory at the 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH). All in- hospital HIV positive patients 
with thrombocytopenia for whom a bone marrow investigation had been performed were considered 
eligible, and between August 2009 and January 2010, 78 patients were enrolled.  
2.2 Ethical clearance: 
Ethical clearance was obtained from the Human Research Ethics Committee of the University of the 
Witwatersrand, Johannesburg. 
REFERENCE:  R14/49 Dr Jenifer Vaughan 
CLEARANCE CERTFICATE:  M090113 
Informed consent was obtained from all participants. 
2.3 Sample collection and analysis: 
A venous blood sample was collected from each participant in a tube anti-coagulated with EDTA. This 
was used to perform a full blood count and reticulocyte count (which includes the IPF as one of the 
parameters measured) using a Sysmex XE-5000 haematology analyzer (Sysmex, Kobe, Japan) within 
24 hours of sample collection.  (The IPF has been shown to remain stable for at least 2 days after 
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collection if stored at room temperature [45]). If available, a sample collected from the patient on the 
day of the bone marrow investigation for the purpose of routine blood count analysis was used, 
provided that the sample was of adequate quantity and had not yet been filed for storage in the 
refrigerator.  In the event that an adequate recent specimen was not available, a fresh sample was 
collected from the patient by the investigating doctor as soon as possible (and within 24 hours of the 
bone marrow investigation).  
 
The platelet count measured using the Sysmex XE-5000 instrument (Sysmex, Kobe, Japan) was 
recorded as the baseline platelet count. When available, the platelet count measured on routine full 
blood count analysis in the same sample (performed in the haematology laboratory using either a 
Beckman-Coulter LH750 haematology analyzer (Beckman-Coulter, Brea, CA), or a Bayer Advia 2120 
analyzer (Siemens Medical Solutions Diagnostics, Zurich, Switzerland) was documented, and results 
compared with those measured on the Sysmex XE-5000 (Sysmex, Kobe, Japan).  This was done in 
order to verify agreement between results from the various instruments, as the follow-up platelet 
counts documented were those measured in the routine laboratory (see 2.1.8).  
 
2.4 Quality control: 
Quality assurance was performed using normal, abnormal high, and abnormal low quality control 
materials supplied by the manufacturer on a daily basis. 
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2.5 Precision and accuracy studies: 
As there is no readily available gold standard method to assess reticulated platelets, precision and 
accuracy studies were performed on the Sysmex XE-5000 instrument (Sysmex, Kobe, Japan) using 
control materials with a designated IPF value. 
 
2.6 Bone marrow assessment: 
Analysis of the bone marrow aspirate and trephine biopsy morphological features were undertaken 
by a single experienced morphologist using a Nikon ECLIPSE E400 microscope (Nikon, Tokyo, Japan). 
The bone marrow aspirate samples were stained with the May-Grünwald-Giemsa stain, and the 
trephine biopsies with haematoxylin and eosin. Megakaryocyte numbers and morphology were 
documented in addition to any other findings judged to be pertinent (such as the presence of a 
malignant or infectious infiltrate).  Photographs of some of the interesting pathology were taken 
using an Altra 20 digital camera (Soft Imaging System, Hamburg, Germany).  
 
2.7 Clinical information: 
Patient information was gathered from the hospital file and the laboratory computer system records. 
Information collected included details about the presenting complaint, the favored diagnosis (as 
judged by the treating clinician), any history of previous medications, past medical problems, 
treatment instituted for the primary cause of the thrombocytopenia by the treating clinician, the CD4 
count, TB culture results and any other information judged to be pertinent on a case to case basis.  
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2.8 Platelet response to therapy: 
A follow-up platelet count was recorded from the laboratory computer records as close to 1 week 
after the bone marrow investigation as possible, or at patient death/discharge from the hospital if 
the latter occurred less than 7 days after the bone marrow was performed. This was done in order to 
document the short-term platelet response to therapy instituted. This platelet count result was 
obtained from sample analysis on one of the haematology analyzers in routine use in the CMJAH 
haematology laboratory at this time, which included a Beckman-Coulter LH750 (Beckman-Coulter, 
Brea, CA) and a Bayer Advia 2120 (Siemens Medical Solutions Diagnostics, Zurich, Switzerland).  
 
All clinical decisions and the physical management of the patient were undertaken by the attending 
clinician. 
 
2.9 Study definitions: 
2.9.1 Definition of Thrombocytopenia: 
For the purposes of this study, thrombocytopenia was defined as a platelet count below 140x10^9/l 
in the absence of platelet clumping. 
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2.9.2 Thrombocytopenia severity grading: 
Thrombocytopenia severity was graded as follows: 
 
Platelets <25 = Grade Four Thrombocytopenia  
Platelets 25-50 = Grade Three Thrombocytopenia 
Platelets 51-75 = Grade Two Thrombocytopenia 
Platelets 76-139 = Grade One Thrombocytopenia 
This is in accordance with the National Cancer Institute common terminology criteria [47]. 
2.9.3 IPF cut-off: 
The IPF was judged to be low/normal if less than or equal to 7.7%, and increased if more than 7.7%. 
This is in accordance with the recommendations made in reference 44. 
2.9.4 Megakaryocyte dysplasia quantification:  
Megakaryocyte dysplasia was quantified as the number of megakaryocytes judged to have abnormal 
or degenerate morphology out of every 30 megakaryocytes present. This was undertaken in an effort 
to grade the degree of megakaryocyte dysplasia noted (in accordance with the recommendations 
made in reference 30). 
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2.9.5 Response to treatment: 
Response to treatment was defined according to recently published recommendations [48]. They are 
as follows: 
 If the original platelet count was less than 30x10^9/l, the follow-up platelet count was 
required to have reached a minimum level of at least 30x10^9/l and to have doubled its 
base-line.  
 If the original platelet count was between 31-50x10^9/l; the platelet count was required 
to have doubled from its baseline. 
 If the platelet count was between 50 and 99x10^9/l, it was required to have reached a 
level of at least 100x10^9/l. 
Because no published guidelines are available for assessment of response to treatment in patients 
with very mild thrombocytopenia (>100x10^9/l), a response to treatment was defined as 
normalization of the platelet count. 
 
2.10 Data Analysis 
Agreement in platelet count between the routinely used haematology analyzers and the Sysmex XE-
5000 was assessed using the Bland-Altman method of comparison. 
Parametric data (such as comparisons of the platelet count between groups) was analyzed using a 
student t-test, and non-parametric data (such as comparisons between the IPF distribution (high vs 
low) in relation to variables of interest), was analyzed using the Fisher’s exact test and logistic 
regression. In addition, odds ratios were calculated to assess the likelihood of the IPF being high or 
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low in the presence of various variables of interest, both before and after correction for confounding 
variables by means of logistic regression. These odds ratios are expressed as crude and adjusted odds 
ratios respectively.   
 
Platelet count response in relation to the IPF as well as in relation to other clinical variables of 
interest was analyzed by means of contingency tables and odds ratios. 
 
 P values less than or equal to 0.05 were considered statistically significant, and values between 0.05 
and 0.1 were considered to be of marginal statistical significance. 
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Chapter 3:   
3.0 Results 
3.1 Precision and accuracy analysis of the IPF parameter. 
This was performed using control material with a known IPF value of between 18 and 23%. Repeat 
analysis of this control material revealed a mean IPF of 21.7% over 11 runs, with a standard deviation 
of 1.16%, and a co-efficient of variation of 5.3%.  
3.2 An overview of the patient cohort. 
3.2.1 General information 
3.2.1.1 Patient demographics (summarized in Table 3.1): 
Of the 78 patients enrolled, 34 (44%) were female, and 44 (56%) were male. Their mean age was 37 
years, (ranging from 21 to 67 years).   
All but one of the patients were of African descent. 
3.2.1.2 HIV-related information (summarized in Table 3.1): 
A CD4 count was available in 70 of the patients, with a mean CD4 count of 106 (ranging from 
1x10^6/l to 761x10^6/l, median = 67x10^6/l). Sixty one (87%) had a CD4 count of less than 
200x10^6/l, and were therefore categorized as having immunological AIDS. In addition, two of the 
nine patients who had a CD4 count greater than 200x10^6/l had AIDS defining pathologies.   
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Twenty (26%) of the patients were on ARV therapy, five (25%) for between one week and two 
months duration, and 15 (75%) for a minimum of three months duration. These patients had a mean 
CD4 count of 84x10^6/l, with only one patient having a CD4 count over 200x10^6/l.  
Viral loads were available in 21 patients, eight on ARVs, and 13 not on ARVs. Among patients on 
ARVs, the mean viral load was approximately 375 500 copies/ml, while the mean viral load in patients 
not on ARVs was over I 860 000 copies/ml.  
Of the seven patients without AIDS, three had ITP, one had TTP and none had TB. 
Table 3.1: A summary of patient demographic and HIV-related data. 
Sex: 
     Male: 
     Female:  
 
56% 
44% 
Mean age: 
 
37 years (Range: 21-67 years) 
Mean CD4 count (N=70): 
 
106x10^6/l (Range: 1-761x10^6/l, median: 67x10^6/l) 
ARV therapy: 
       Yes: 
           < or equal to 2 months duration: 
            > or equal to 3 months duration: 
       No: 
 
26% 
     25% 
     75% 
74% 
Mean Viral load (N=21): 
        On ARVs: 
        Not on ARVs: 
 
375 500 copies/ml 
I 860 000 copies/ml 
 
3.2.1.3 Blood counts: 
The mean blood counts are displayed in Table 3.2: 
Only one patient had an isolated thrombocytopenia, and 33 (42%) had a pancytopenia.  
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Table 3.2 Mean full blood count parameters and their ranges.  
Parameter Mean Range 
Platelet count: 56x10^9/l 4-137 x10^9/l 
Haemoglobin 8g/dl 4.7-12.5 g/dl 
White cell count:  4.6x10^9/l 0.6-14.5x10^9/l 
Mean cell volume:  85 fl 67-101 fl 
 
The various grades of thrombocytopenia (grade one to four) were fairly evenly represented in the 
cohort, with 27% having grade four thrombocytopenia, 22% grade three, 20% grade two and 31% 
grade one (see Figure 3.1). 
 
  
Figure 3.1: Platelet count distribution in the entire cohort of patients (N=78)  
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3.2.1.4 IPF data: 
Of all patients, 41 (53%) had a low IPF, and 37 (47%) had a high IPF (see Figure 3.2). The mean IPF was 
9,5%, ranging from 1,3-44%, with a median value of 7,6%. 
In patients with grade two and three thrombocytopenia, the proportion with a high IPF was similar to 
the proportion with a low IPF. However, among patients with grade four thrombocytopenia, 17 (81%) 
had a high IPF (mean IPF 14%), while 22 patients with grade one thrombocytopenia (92%) had a low 
IPF (mean IPF 6%) (see Figure 3.3). The difference in IPF distribution between patients with grade one 
and grade four thrombocytopenia was found to be highly statistically significant (p=<0,001). In fact, 
the proportion of patients with a low IPF level among those with grade one thrombocytopenia was 
statistically different from that seen in patients whose platelet counts fell within all of the other 
grades of thrombocytopenia (see Table 3.3).  In contrast, the different proportions of high IPF levels 
between patients with grade four thrombocytopenia as compared to grade three was only marginally 
significant (p=0.087), and the difference between grade four and grade two did not reach statistical 
significance at all (p=0.151) (see Table 3.4). 
 
 
Figure 3.2: IPF distribution in the entire cohort (N=78) 
1
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IPF>7.7% 47%
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Figure 3.3: IPF distribution relative to platelet count 
 
 
Table 3.3:  Statistical analysis of the proportion of low IPFs in all grades of thrombocytopenia as 
compared to grade 1. 
 Proportion of 
cases with a low 
IPF 
Odds 
Ratio 
95% Confidence 
interval 
p-value 
Grade 1 thrombocytopenia (N=24) 
 
 
Grade 2 thrombocytopenia (N=16) 
92% 
 
 
44% 
14 (2.7-71.8) 0.003 
Grade 1 thrombocytopenia (N=24) 
 
 
Grade 3 thrombocytopenia (N=17) 
92% 
 
 
47% 
12 
 
 
 
 
(2.4-61.5) 0.003 
Grade 1 thrombocytopenia (N=24) 
 
 
Grade 4 thrombocytopenia (N=21) 
92% 
 
 
19% 
47 (8.2-257.4) <0.001 
 
Table 3.4:  Statistical analysis of the proportion of high IPFs in all grades of thrombocytopenia as 
compared to grade 4. 
Plts< or 
= 25 
(Grade 
4)
Plts 26-
50 
(Grade 
3)
Plts 51-
75 
(Grade 
2)
Plts>75 
(Grade 
1)
IPF < or = 7.7% 19% 47% 44% 92%
IPF >7.7% 81% 53% 56% 8%
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 Proportion of 
cases with a high 
IPF 
Odds 
ratio 
95% Confidence 
interval 
p-value 
Grade 1 thrombocytopenia (N=24) 
 
Grade 4 thrombocytopenia (N=21) 
 
8% 
 
81% 
0.021 (0.004-0.22) <0.001 
Grade 2 thrombocytopenia (N=16) 
 
Grade 4 thrombocytopenia (N=21) 
 
56% 
 
81% 
0.3 (0.073-1.258) 0.15 
Grade 3 thrombocytopenia (N=17) 
 
Grade 4 thrombocytopenia (N=21) 
 
53% 
 
81% 
0.265 (0.066-1.080) 0.087 
 
3.2.1.5 Spectrum of Pathology: 
 Mycobacterial infection was diagnosed in 38 (49%) of the patients, and 31 of these had evidence of 
bone marrow involvement (as evidenced by either the presence of granulomatous infiltration and or 
acid fast bacilli visualized in the trephine biopsy, or a positive bone marrow TB culture) (see Figure 
3.4).  Two of these patients had Mycobacterium avium complex infection (see Figure 3.5), while the 
rest had either culture evidence or morphological characteristics more compatible with 
Mycobacterium tuberculosis.  
Eight patients (10%) had bone marrow infiltration by a malignancy. Two had a large B-cell lymphoma 
unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt 
lymphoma (see Figure 3.6), one had plasmablastic lymphoma (see Figure 3.7), three had Hodgkin 
lymphoma (see Figure 3.8), one had a peripheral T-cell lymphoma (see Figure 3.9) and one had 
metastatic carcinoma of the breast (see Figure 3.10).  Four of these patients had very extensive 
marrow infiltration, with marked displacement of normal bone marrow elements. The remaining four 
patients had focal bone marrow infiltration, with well preserved residual haemopoiesis. One of the 
patients with extensive marrow infiltration by large B-cell lymphoma unclassifiable with features 
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intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma also had pulmonary TB 
(as diagnosed by demonstration of acid fast bacilli in her sputum).  
  
 
 
Figure 3.4: Granulomatous infiltration of the bone marrow in one of the patients with 
Mycobacterium tuberculosis infection. Normal marrow architecture is preserved on the left, while the 
right hand side of the image shows an infiltrate comprised of epithelioid histiocytes with caseous 
necrosis. The black arrow shows a Langhans giant cell, and the red arrows show megakaryocytes 
within the preserved bone marrow expanses (haematoxylin and eosin stain, 10x magnification). 
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Figure 3.5: A high power view of a Ziehl-Neelsen stain showing macrophages containing numerous 
acid fast bacilli (see arrow) in one of the patient’s with Mycobacterium avium complex infection ( 40x 
magnification). 
 
 
            
A             B 
Figure 3.6: A shows the cytology of a tumour cell from one of the cases of large B- cell lymphoma 
unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt 
lymphoma. The cell is intermediate in size with deeply basophillic, vacuolated cytoplasm (May-
Grünwald-Giemsa stain, 50x magnification). B is histology of this case, showing tingible body 
macrophages (black arrows) and  brisk mitotic activity (red arrows) (haematoxylin and eosin stain, 
40x magnification).  
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A         B 
Figure 3.7: Histology of the case of plasmablastic lymphoma (haematoxylin and eosin stain, 40x 
magnification). B is an inset of the tumour cells, showing plasmacytoid morphology (100x 
magnification). 
 
 
 
 
Figure 3.8: Histology of one of the cases of Hodgkin lymphoma. This picture shows a Reed-Sternberg 
cell (see arrow) in a rich inflammatory background (haematoxylin and eosin stain, 40x magnification). 
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A       B 
Figure 3.9:  Histology of the case of peripheral T-cell lymphoma. In A, the area of infiltration is seen 
in the top right hand corner (see arrow), while normal haemopoiesis is preserved in the rest of the 
specimen (haematoxylin and eosin stain, 10x magnification). B shows a high power view of the 
infiltrate, which is comprised of hetereogeneously sized lymphocytes in a histiocyte-rich background 
(haematoxylin and eosin stain, 40x magnification). 
 
 
 
         
A       B 
Figure 3.10 :  A Extensive marrow infiltration by carcinoma of the breast (haematoxylin and eosin 
stain, 10x magnification). B is a high power view of non-haemopoietic cells forming pseudo-glandular 
structures (haematoxylin and eosin stain, 40x magnification). 
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Two patients were ultimately diagnosed with TTP (see Figure 3.11), and ten with ITP. One of the 
patients diagnosed with ITP had a co-existing peripheral T-cell lymphoma, and one of the patients 
with TTP also had TB complicated by a pleural effusion. Three of the patients with ITP and one of the 
patients with TTP had CD4 counts greater than 200x10^6/l. These four patients represent more than 
half of the patients without AIDS. 
Fourteen patients were found to have hypocellular marrow, and in four of these, absolute 
megakaryocyte numbers appeared significantly reduced. Within the hypocellular group, two patients 
had positive bone marrow TB cultures without frank granuloma formation, and one patient had 
disseminated Cryptococcus infection (see Figure3.12). 
 
 
 
Figure3.11: Shows a case of TTP with marked red cell fragmentation and diffuse basophilia. No 
platelets are present in this field (May-Grünwald-Giemsa stain, 50x magnification). 
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A       B  
Figure 3.12: Disseminated Cryptococcus infection. A shows a low power view of the bone marrow 
trephine, demonstrating the hypocellular nature of the sample (haematoxylin and eosin stain, 4x 
magnification), and B shows a high power view of several macrophages laden with encapsulated 
fungal organisms (see arrows) (haematoxylin and eosin stain, 40x magnification). 
 
Patients on ARVs had a similar spectrum of pathology to patients not on ARVs. Statistically, there was 
no difference between the prevalence of either ITP or TB between the two patient groups, while a 
slight trend was noted toward more malignancies in patients on ARVs,  which was not found to be 
statistically significant (p=0.42) (see Table 3.5). Likewise, the mean CD4 and platelet counts did not 
differ between patients treated with ARVs as compared to  those who were not (p=0.73 and 1 
respectively), and their distribution of platelet grades appeared very  similar (see Figure 3.13).  
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Table 3.5 : Distribution of pathology among patients on and not on ARVs.  
 ARVs Y (N=20) ARVs N (N=58) Odds Ratio p-value 
BM TB (N=31) 8 (40%) 23 (40%) 1.01 1 
ITP (N=10) 2 (10%) 8 (14%) 0.69 1 
Malignant BM 
infiltration (N=8) 
3 (15%) 5 (9%)  1.9 0.42 
 
 
 
Figure 3.13: A comparison of the distribution of platelet grades among patients on ARVs as 
compared to those not on ARVs. 
 
3.2.1.6: Bone marrow morphology findings: 
The bone marrow aspirate and or trephine biopsy were adequate for morphological assessment in 
72(92%) of the 78 patients. Among these samples, megakaryocyte numbers were considered 
adequate in 63 (88%). The remaining nine patients had either hypocellular marrow with an absolute 
reduction in all cell lines, or extensively infiltrated marrow. As a rule, megakaryocyte activity was 
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better judged on the trephine biopsy, with sample quality of the bone marrow aspirates rendering 
confident assessment of megakaryopoiesis difficult in 41 cases (57%). Megakaryocyte morphology 
assessment was performed if a minimum of 10 megakaryocytes were present in a specimen, and was 
therefore possible in 70 patients. Among these, disordered or degenerate megakaryocytes comprised 
greater than 10% of all megakaryocytes assessed  in 53 (76%) patients, and more than 30% in 18 
(26%).  
Among patients with bone marrow infiltration by TB, 29 cases had sufficient megakayocytes present 
to assess megakarycoyte morphology. Of these, 27 (93%) were judged to have sufficient 
megakarycoyte numbers. 
Figures 3.14, 3.15 and 3.16 show examples of abnormal megakaryocyte morphology from the cohort. 
 
 
               
A         B 
Figure 3.14: Showing cytological examples of abnormal megakaryocytes. A shows hypolobation, 
while B shows hyperlobation (May-Grünwald-Giemsa stain, 50x magnification).   
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Figure 3.15: Shows histology of a bizarrely nucleated megakaryocyte (black arrow), a bare 
megakaryocyte nucleus (red arrow) and a morphologically unremarkable megakaryocyte (blue arrow) 
(haematoxylin and eosin stain, 40x magnification). 
 
 
 
Figure 3.16: Shows histology of two hyerplobated megakaryocytes (haematoxylin and eosin stain, 
40x magnification). 
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3.3 The IPF relationship to various variables of interest: (Summarized in 
Table 3.6) 
Because of the very strong association between IPF and platelet count, the relationship between the 
IPF and all other variables of interest were adjusted for the thrombocytopenia grade by logistic 
regression. 
3.3.1 IPF in relation to HIV-related variables:    
Because 90% of the cohort had AIDS, meaningful comparison between the IPF in patients with and 
without AIDS was not possible. Therefore, the IPF distribution was compared between patients with 
severe immunodeficiency (as defined by a CD4 count less than or equal to 50x10^6 cells/l) and 
patients with more moderate CD4 T-cell depletion. This revealed no difference in the proportion of 
patients with high versus low IPF values between these two groups (see Figure 3.17). Similarly, the 
IPF distribution was not different between patients on and not on ARVs. However, patients with 
lower viral loads showed a marginally significant tendency to have a low IPF as compared to patients 
with high viral loads (p=0.067) (see Figure 3.18). Unfortunately, logistic regression to eliminate the 
possible confounding effect of thrombocytopenia severity was not possible in this subgroup due to 
the very limited sample number, but the mean platelet count did not differ between the two groups 
(p=0.5) (see Figure 3.19). 
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Figure 3.17: A comparison of the IPF distribution among patients with severe immunodeficiency 
(CD4 < or = to 50) compared to those with more moderate immunodeficiency (CD4 >50) (N=70). This 
figure illustrates that the IPF distribution between these 2 groups is very similar. 
 
 
 
Figure 3.18:  A comparison of the IPF distribution among patients with low viral loads (< 10 000 
copies per ml) compared to those with higher viral loads (N=21). This figure illustrates a markedly 
different IPF distribution between the 2 groups, with the proportion of patients having a low IPF 
being appreciably higher among those with low viral loads (p=0.067). 
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Figure 3.19: A comparison of the distribution of thrombocytopenia grade among patients with low 
viral loads (< 10 000 copies per ml) compared to those with higher viral loads. This figure illustrates a 
relatively marked difference between the groups, with patients with low viral loads tending to have 
more grade1/2 and less grade 3/4 thrombocytopenia overall. 
 
 
3.3.2: IPF distribution in relation to underlying pathology: 
Among patients with TB (both with and without bone marrow involvement), no difference in the IPF 
distribution was noted as compared to patients without TB.  Patients with ITP and TTP showed a 
significantly higher proportion of cases with a high IPF as compared to patients without these 
conditions. However, when adjusted for the confounding effect of thrombocytopenia grade, this 
association lost statistical significance due to the high proportion of patients (8 (67%) out of 12) 
within this subgroup having severe thrombocytopenia. In contrast, patients with hypocellular bone 
marrow had a significant increase in the proportion of cases with a low IPF as compared to patients 
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with normal or increased cellularity, which remained statistically significant when adjusted for the 
effect of thrombocytopenia severity. 
 
Unfortunately, meaningful statistical analysis was not possible among the patients with malignant 
infiltration of the bone marrow due to the small sample number and the heterogeneous nature of 
the pathologies represented. Therefore, patients in whom the broad mechanism of 
thrombocytopenia was likely to be similar (i.e. a product of bone marrow dysfunction as opposed to 
peripheral destruction or consumption) were pooled for the purposes of statistical analysis in order 
to counter the limitations of sample size. Among patients with either hypocellular marrow or 
extensive marrow infiltration, (in whom the cause of thrombocytopenia is most likely central in 
origin),  a trend was noted towards the occurrence of a low IPF level more frequently as compared to 
the global cohort. This difference became statistically significant on adjustment for the effects of the 
thrombocytopenia grade (p= 0.0465). 
3.3.3: IPF in relation to megakaryocyte morphology: 
A trend was noted toward the more frequent occurrence of a low IPF level in patients with a 
significant degree of megakaryocyte disorder. However, this weak association was lost on adjustment 
for thrombocytopenia grade.  Similarly, no relationship with the IPF could be established among 
patients with more gross megakaryocyte dysplasia (as defined as morphological atypia in more than 
30% of megakaryocytes assessed). 
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     Table 3.6:  Summary of the relationship between the IPF and variables of interest. 
 Mean 
IPF: 
Proportion 
with a low 
IPF 
Crude 
Odds 
Ratio 
95% 
Confidence 
interval 
p-
value 
Adjusted 
Odds 
Ratio 
95% 
Confidence 
Interval 
p-
value 
CD4 < or = 50 (N=28) 
 
CD4>50 (N=42) 
9.2% 
 
9.9% 
54% 
 
50% 
1.15 (0.45-3.0) 0.81 0.75 (0.23- 2.5) 
 
0.64 
ARVs Y (N=20) 
 
ARVs N (N=58) 
9.2% 
 
9.6% 
50% 
 
53% 
0.87 (0.30-  2.4) 0.8 0.74 (0.20-  2.7) 
 
0.65 
HIV VL > or = 10 000 
cp/ml (N=13) 
 
HIV VL < 10 000 cp/ml 
(N=8) 
10.7% 
 
 
6% 
39% 
 
 
88% 
0.09 (0.01-  1.4) 0.067 - - - 
BM TB (N=31) 
 
No evidence of BM TB 
(N=47) 
9% 
 
9.9% 
58% 
 
49% 
1.4 (0.52- 3.4) 0.54 0.85 (0.27- 2.7) 0.77 
TB at any site (N=38) 
 
No evidence of current 
TB (N=40) 
9% 
 
9.9% 
53% 
 
53% 
1.01 (0.42-2.4) 1 0.95 (0.32- 2.8) 0.94 
ITP/TTP (N=12) 
 
Non- ITP/TTP (N=66) 
14.8% 
 
8.5% 
25% 
 
58% 
0.25 (0.06-   1.0) 0.058 0.57 (0.1-3.0) 0.5 
Hypocellular Marrow 
(N=14) 
 
Normo- or hypercellular 
marrow (N=58) 
6.2% 
 
 
10.4% 
79% 
 
 
47% 
4.16 (1.12-15.0) 0.04 5.6 (1.2- 27.1) 0.032 
Hypocellular OR 
extensively infiltrated 
marrow (N=18) 
 
Normo/Hypercellular 
marrow without 
extensive marrow 
infiltration (N=54) 
7% 
 
 
 
10.4% 
 
67% 
 
 
 
48% 
2 (0.7-6.2) 0.19 4 (1-16.2) 0.047 
< or = 10% Disordered 
megakaryocytes (N=17) 
 
>10% Disordered 
megakaryocytes (N=53) 
12.5% 
 
 
8.6% 
41% 
 
 
58% 
 
0.5 (0.16-1.5) 0.27 0.8 (0.21- 3.1) 0.75 
< or = 30% Disordered  
megakaryocytes (N=52) 
 
>30% Disordered 
megakaryocytes (N=18) 
9.9% 
 
 
8.6% 
48% 
 
 
61% 
0.69 (0.23-2.1) 0.59 1.1 (0.25- 4.6) 0.9 
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Table 3.7: IPF distribution among patients with grade 4 thrombocytopenia with and without 
ITP/TTP. 
 Proportion with 
a low IPF 
Odds Ratio 95% Confidence 
Interval 
p-value 
ITP/TTP (N=8) 
 
Non-ITP/TTP 
(N=13) 
14% 
 
23% 
 
0.48 (0.06-4.3) 1.0 
 
3.4 Platelet count response analysis: 
3.4.1 Agreement between the platelet count measured on the Sysmex XE-
5000 and the platelet count measured in the routine laboratory: 
A platelet count from the routine haematology laboratory was available in 68 of the 78 patients.  
 Bland-Altman analysis revealed no mean difference between platelet counts measured in the routine 
laboratory and the platelet count measured during IPF analysis, with 95% limits of  agreement 
ranging from -19x10^9/l to 19x10^9/l (see Figure 3.20). Therefore, the instruments showed good, but 
imperfect agreement.  
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             Bland-Altman:Difference in platelet count vs
              average platelet count (All patients:  N=68)
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Figure 3.20: The results of Bland-Altman analysis of the difference between platelet counts 
measured in the routine laboratory and those measured on the Sysmex instrument relative to the 
average of the 2 platelet counts (N=68).  The graph shows acceptable agreement between the 2 sets 
of instruments with very few outliers. The mean difference between platelet counts was                                
-0,03x10^9/l, with 95% limits of agreement ranging from -19x10^9/l to 19x10^9/l. 
  
 
As follow-up platelet counts were only available from the routine laboratory, response assessment 
was only analyzed amongst those patients for whom a baseline routine platelet count was available 
in the interests of maximum consistency (in view of the small differences in platelet count 
measurements between the two sets of instruments). The follow-up platelet count was compared 
with the original routine platelet count and not the platelet count measured on the XE-5000. 
Therapy response data was therefore available in 49 patients; a minimum of 3 days after the bone 
marrow investigation was performed. 
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3.4.2 Platelet count responses: 
Of the 49 patients with both baseline and follow-up routine platelet counts, 21 (43%) showed a 
positive response in their platelet count, and 28 (57%) did not. The IPF distribution in the 49 patients 
was not different from the total cohort (p=0.53).  
 Amongst the 21 therapy responders, the mean platelet count was 46x10^9/l and the IPF was high in 
11 (52%), while the mean platelet count was 47x10^9/l with a high IPF in 13 (46%) of the 28 therapy 
non-responders.  The proportion of patients with a high IPF was therefore not statistically different 
between therapy responders and non-responders. 
On analysis of the spread of various IPF levels between the two groups, the distribution of very high 
and very low IPFs appeared similar (see Figure 3.21). 
 
Figure 3.21: The IPF distribution in the therapy responders (red) as compared to therapy non-
responders (blue) (N=49).The distribution of both very high and very low IPFs appears similar 
between the 2 groups.  
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Further analysis of the 28 patients who failed to respond to therapy revealed that 13 (46%) actually 
experienced a fall in their platelet count over follow-up, while 7(25%) experienced an improvement in 
platelet count of less than 50%. However, eight (29%) of the patients categorized as non-responders 
showed a partial response to therapy, with a greater than 50% improvement in their platelet count. 
Four of these eight patients had severe thrombocytopenia at presentation, and had more than 
doubled their platelet count over the follow-up period, but had not achieved a platelet count over 
30x10^9/l (see Table 3.8). 
Table 3.8: Four patients categorized as therapy non-responders because their platelet count had not 
achieved a level above 30x10^9/l. 
 
 
Two of the remaining four patients had a baseline platelet count between 20 and 25x10^9/l, which 
improved in both cases by greater than 50% and achieved a  level greater than or equal to 30x10^9/l, 
but did not double.  
Among the eight non-responders who had experienced a minimum of a 50% improvement in their 
platelet count, six (75%) had a high IPF, while among the other 20 non-responders, only seven (35%) 
had a high IPF. In the 13 patients whose platelet counts dropped, six (46%) had a high IPF. 
Original platelet count 
(x10^9/l) 
Follow-up platelet count 
(x10^9/l) 
6 15 
7 20 
10 24 
6 27 
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The mean platelet count was significantly lower in the partially responding group (mean platelet 
count= 19x10^9/l) as compared to the complete non-responders (mean= 53x10^9/l) (p-value: 0.012). 
 
Because it would be clinically useful to be able to distinguish patients who were going to experience 
at least a partial response in their platelet count (to a minimum level greater than 20x10^9/l, which is 
considered to be safe from spontaneous haemorrhage [16]) from those who were not going to 
respond at all, further analysis was carried out to assess the power of the IPF to distinguish these two 
patient subsets from each other.  Any patient who showed a significant change in the platelet count, 
but did not achieve a level greater than 20x10^9/l was classified as a complete non-responder.  
Among the 28 patients who were either complete or partial therapy responders, 16 (57%) had a high 
IPF, while only 8 (38%) had a high IPF among the 20 patients classified as complete non-responders.  
Despite this apparent difference in the number of high IPF levels between the two groups, the sample 
numbers were insufficient to prove statistical significance (p=0.25). The mean platelet count was 
41x10^9/l and 54x10^9/l respectively in these groups, and again, this difference was not found to be 
statistically significant (p=0.19). 
 
Closer inspection of the data reveals that the distribution of very high IPF levels is significantly 
different in the two populations.  Amongst the 28 patients who show at least a significant positive 
trend in their platelet count,  15( 54%) had an IPF greater than 10%, and amongst the 21 patients 
with very poor responses to treatment,  15 (72%) had an IPF less than 8% (see Figure 3.22). 
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Figure 3.22: The IPF distribution among all therapy responders (including partial responders) as 
compared to complete non-responders (N=49). The IPF distribution among patients with at least a 
partial therapy response (blue) appears dissimilar to the IPF spread among those patients who were 
complete non-responders (red), with the former group showing a predominance of IPF levels greater 
than 10%, and the latter group generally having an IPF of <8%.  
 
 
In view of the apparent predominance of patients with an IPF level greater than 10% among those 
who showed a positive trend in their platelet count over time, further subgroup analysis was 
performed using 10% as a novel IPF cut-off.  Results are displayed in Table 3.9 below: 
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 45 
 
Table 3.9: Summary of the results of contingency table analysis of platelet count response in relation 
to IPF, with an IPF cut-off of 10%. 
 
 
To best identify patients who show complete non-response to therapy, further analysis was 
performed to identify the best IPF cut-off to discriminate this sub-group of patients. Results are 
summarized in Table 3.10 below: 
Table 3.10: Results summary of contingency table analysis of complete failure to respond to therapy 
in relation to IPF. 
 
 
 
 
 IPF>10  
Sensitivity 54% 
Specificity 81% 
Positive predictive value 79% 
Negative predictive value 57% 
Odds Ratio (of positive 
platelet response if IPF 
>10%) 
4.9 
95% Confidence Interval 1.4-17.4 
P-value 0.019 
 IPF <8  IPF<6  
Sensitivity 71% 33% 
Specificity 57% 89% 
Positive predictive value 56% 70% 
Negative predictive value 73% 64% 
Odds Ratio (of no platelet 
response if IPF low) 
3.3 4.2 
95% Confidence Interval 1-10.9 0.99-17.2 
P-value 0.081 0.076 
 46 
 
3.4.3 Analysis of short –term platelet count response among various patient 
subsets. 
 
Results of analysis of platelet count response (as originally defined in 2.9.5) among patient subsets of 
clinical interest are summarized in Table 3.11.  
Briefly, analysis revealed significantly better responses in patients on anti-retroviral therapy and a 
trend toward worse platelet responses among patients with a CD4 count less than 50, those with high 
viral loads (i.e.>10 000 copies per ml), and those with bone marrow infiltration by TB. No significant 
differences were present between the responses in patients with platelet counts less than 50x10^9/l 
as opposed to those with higher platelet counts, or in those with or without a significant degree of 
megakaryocyte dysplasia. The latter was assessed among patients with less than or equal to 10% 
megakaryocyte disorder as compared to those with more than 10% disorder, as well as in patients 
with disorder in less than or equal to 30% of their megakaryocytes as compared to those with more 
than 30% morphological dysplasia.   
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Table 3.11: Summary of platelet count responses in various patient sub-groups. 
 Proportion 
without a 
platelet 
count 
response. 
Odds 
Ratio 
95%  
Confidence 
 Interval 
P-value 
Plts < or = 50 (N=30) 
 
Plts >50 (N=19) 
57% 
 
58% 
0.95 (0.3-  3.0) 
 
1 
Megakaryocyte disorder >10% 
(N=31) 
 
Megakaryocyte disorder < or = 
10% (N=13) 
 
 
Megakaryocyte disorder >30% 
(N=10) 
 
Megakaryocyte disorder < or = 
30% (N=34) 
58% 
 
 
46% 
 
 
 
40% 
 
 
58% 
 
 
1.62 
 
 
 
 
 
 
0.47 
 
(0.4-6.1) 
 
 
 
 
 
 
(0.1-2.0) 
0.52 
 
 
 
 
 
 
0.472 
 
BM TB infiltration Y (N=19) 
 
BM TB infiltration N (N=30) 
68% 
 
 
50% 
2.2 (0.67-7) 0.25 
CD4< or= 50 (N=15)  
 
CD4>50 (N=30) 
67% 
  
50% 
2 (0.6-7) 0.352 
ARV treatment N (N=35) 
 
ARV treatment Y (N=14) 
69% 
 
29% 
5.5 (1.2-23.9) 0.023 
HIV Viral Load (HIVVL) >10 000 
(N=7) 
 
HIVVL <10 000 (N=6) 
86% 
 
 
33% 
12 (0.97-132) 0.1 
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Chapter 4 
4.0 Discussion: 
4.1 Study limitations: 
 The sample number is relatively small, making statistically significant findings in patient 
subgroups unfeasible in some instances.  
 90% of the cohort had AIDS, which is likely to reflect the frequency of symptomatic 
thrombocytopenia in the setting of HIV. Asymptomatic persons with thrombocytopenia are 
under-represented, possibly because they are less likely to seek medical attention. The 
findings are therefore pertinent predominantly in thrombocytopenic patients with AIDS, and 
cannot necessarily be extrapolated to non-AIDS patients. 
 
4.2 General cohort characteristics:  
The findings are highly representative of the wide spectrum of pathologies that patients with AIDS 
are vulnerable to. In particular, the prevalence of TB in this cohort is remarkable, with nearly half of 
all of the patients having confirmed mycobacterial infection. Although these findings may be 
somewhat biased by the fact that a number of patients had a bone marrow investigation performed 
because TB was suspected clinically (and not to investigate the thrombocytopenia per se), the major 
burden of TB in South Africans with AIDS is nonetheless clearly highlighted. Among patients without 
AIDS, a very significant prevalence of immune-mediated thrombocytopenia was noted, while 
disseminated TB did not occur. Overall, therefore, the spectrum of disease seen in both patients with 
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and without AIDS concurred with the previously described pathology patterns in these respective 
groups [1].     
 
 The proportion of patients with AIDS in the cohort receiving ARV therapy also correlates closely with 
published South African epidemiological data in this regard [3].  Interestingly, although patients on 
ARVs showed evidence of virological control (as manifest by a reduction in their viral loads), the 
majority had persistently low CD4 counts, and similar prevalence’s of disseminated TB, ITP and 
malignancies as compared to  patients not on ARVs . 
4.3 General IPF findings:  
The distribution of high and low IPF levels in patients with various grades of thrombocytopenia  was 
found to be significantly different, with low IPF levels being far more prevalent among patients with 
mild reductions in their platelet counts, and high IPF levels being more common in patients with 
more severe thrombocytopenia.  This finding suggests that a degree of marrow suppression is the 
dominant cause of mild thrombocytopenia in patients with AIDS, while peripheral mechanisms 
predominate among patients with lower platelet counts (most notably in those with grade four 
thrombocytopenia). This may reflect a general tendency for peripheral mechanisms to deplete the 
circulating platelet mass to a greater extent than marrow suppression does in this setting. 
Alternatively, this finding may be a consequence of a blunting of the marrow’s response to mild 
thrombocytopenia in AIDS, regardless of the mechanism, so that an appreciable marrow response is 
only evident when the platelet count falls below a certain threshold. 
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4.4 IPF findings in patient subgroups: 
4.4.1 The IPF in patients with hypocellular or extensively infiltrated marrow 
and ITP/TTP: 
Patients with hypocellular or extensively infiltrated marrow were significantly more likely to have a 
low IPF than patients with normal or increased cellularity without extensive marrow infiltration 
(when adjusted for the effects of thrombocytopenia grade), while patients with ITP/TTP showed a 
marginally significant trend toward having a low IPF level less frequently as compared to the rest of 
the cohort. Unfortunately, the latter finding lost statistical significance on adjustment for the platelet 
count as a result of the heavy prevalence of grade four thrombocytopenia in patients with ITP/TTP, 
(comprising 67% of cases in this sub-group). As IPF levels tended to be elevated in the vast majority of 
patients with grade four thrombocytopenia, (77% in those with non-ITP/TTP, see Table 3.7), the 
apparently higher proportion of high IPF levels in severely thrombocytopenic patients with ITP/TTP 
(86%) was not dramatic enough to achieve statistical significance in the context of the small sample 
size.  Nonetheless, the findings in the above patient sub-groups illustrate very clearly that the IPF 
reliably reflects the mechanism of thrombocytopenia in HIV infected patients in those cases in which 
the cause of the thrombocytopenia is readily apparent by virtue of a combination of the clinical and 
morphological features (as has been demonstrated in HIV-negative patients in the literature 
previously [44, 45]). This finding therefore lends the IPF weight as a tool to demonstrate the 
mechanism causing thrombocytopenia in HIV positive patients when this mechanism is more 
obscure. 
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4.4.2 The IPF in relation to HIV-related variables:  
No association was present between the IPF and either the CD4 count or ARV therapy, suggesting 
that the causes and severity of thrombocytopenia are heterogeneous in these two subgroups. 
However, a marginally significant trend toward the occurrence of a high IPF level in patients with 
higher viral loads was noted. On closer inspection, it is apparent that the IPF distribution in the 
patients with higher viral loads is similar to that of the majority of the cohort, and that the actual 
difference is in the significant number of low IPF levels among the patients with low viral loads. It is 
noted that 4(50%) of the patients with very low viral loads have grade one thrombocytopenia as 
compared to 4(31%) of those patients with high viral loads, while only 1(13%) patient in the group 
with low viral loads has grade four thrombocytopenia, as compared to 5(38%) of the patients in the 
group with higher viral loads (see Figure 3.17). Therefore, it would appear that the difference in IPF 
distribution between patients with high and low viral loads is a product of a difference in the 
distribution of the severity of thrombocytopenia between these two groups (despite similar mean 
platelet counts).  As all but one of the patients with low viral loads were on ARVs (86%) as compared 
to only one of the 13 patients with high viral loads (8%), the possibility that ARVs mediate this 
protection from grade four thrombocytopenia requires consideration. However, the distribution of 
grade one and grade four thrombocytopenia does not appear different between patients who are 
and who are not on ARV therapy in the global cohort (see Figures 3.1 and 3.12). This therefore 
suggests that the positive effects of ARVs on the platelet count only manifest once virological control 
has been established. Because the CD4 count showed no relationship with the viral load (p=0.73), we 
can infer that immune reconstitution is not the principle protective factor at play. Rather, it would 
appear that direct viral effects of HIV itself are a very important contributor to severe 
thrombocytopenia.  
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4.4.3 The IPF in relation to underlying TB: 
No significant difference was found in the IPF distribution among patients with and without TB, 
regardless of whether or not the bone marrow was infiltrated. Two possible explanations for this 
finding have been considered. The first is that unproven mycobacterial infection may be present in a 
significant proportion of patients included in the group without definite evidence of TB, which could 
be blurring any differences between the two groups. This is a very real possibility, given the imperfect 
sensitivity of both microscopy for acid fast bacilli and TB culture [49]. In support of this possibility is 
the fact that three patients included in the non-TB group had sufficient radiological and clinical 
evidence to merit initiation of TB treatment, and a further three patients had been on TB treatment 
for between three weeks and three months. Collectively, these patients comprised 15% of the 
patients without current, proven mycobacterial infection.   
Secondly, the absence of any difference in IPF among patients with and without TB may reflect a 
similar degree of heterogeneity in the underlying mechanism causing thrombocytopenia between the 
two groups, even among patients with definite bone marrow pathology (in whom one might expect 
platelet production failure to be the principle mechanism at play). Indeed, patients with disseminated 
TB are at risk of many causes of peripherally mediated thrombocytopenia, including  hypersplenism 
[50] and DIC [51] (the latter particularly in the context of the acute respiratory distress syndrome 
(ARDS) [52] and the haemophagocytic syndrome [53]). In addition, both ITP [54, 55]  and TTP [56] 
have been reported in association with TB.  In this cohort, four (11%) patients diagnosed with TB had 
splenomegaly, one (3%) had TTP and three (8%) had laboratory evidence of underlying DIC. The high 
IPF levels in many of these patients suggests that these mechanisms are dominant contributors to the 
thrombocytopenia in some cases, and that bone marrow stunting is not necessarily the cause for 
cytopenia’s in patients with frank marrow infiltration. However, it is noteworthy that the IPF level 
was low in nearly 60% of cases with bone marrow TB, despite adequate megakaryocyte numbers in 
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more than 90% of those with samples adequate for assessment of megakaryopoiesis. Clearly, central 
mechanisms (such as ineffective megakaryopoiesis or haemophagocytosis) are important 
contributors to the thrombocytopenia in this setting. 
4.4.4 The IPF in relation to Megakaryocyte Morphology: 
The morphological impression of megakaryocyte adequacy in more than 80% of cases is disparate 
with the presence of a low IPF in more than half of the cohort. In addition, the presence of a 
significant degree of megakaryocyte dysplasia showed no relationship with the IPF (as a reflection of 
megakaryocyte function). These findings highlight the limitations of morphological analysis to 
correctly assess the underlying mechanism of thrombocytopenia, and demonstrate a possible role for 
the IPF in enhancing the morphologist’s ability to interpret the morphological characteristics. 
 
4.5 Short term platelet count response 
4.5.1 Therapy response prediction: 
The results show that an IPF greater than or less than 7,7% is a poor predictor of the short term 
platelet response to therapy when platelet response is defined strictly according to the 
recommendations made in reference 46. However, when therapy response is defined more loosely as 
a greater than 50% improvement in platelet count provided that the follow-up platelet count is more 
than 20x10^9/l, (which is generally believed to be the threshold whereat the risk of spontaneous 
bleeding is increased) as compared to patients who showed either very minimal changes in their 
platelet count or in fact a drop in their platelet count, a trend toward more high IPF levels among 
therapy responders becomes apparent. Although the sample number was inadequate to prove 
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statistical significance of this difference, the distribution of very high IPF levels appears skewed, 
favoring the group who showed some degree of therapy response. When the power of a higher IPF 
cut-off (i.e.10%) to predict platelet count response to treatment  was tested, it was shown that an IPF 
over 10% has strong, statistically significant  specificity and positive predictive value for a minimum of 
a partial response (both in the region of 80%). Similarly, an IPF of less than 6% had a specificity of 89% 
and a positive predictive value of 70% for complete non-response to therapy (p=0.068). In summary, 
the findings suggest that a thrombocytopenic patient with an IPF greater than 10% has a 79% chance 
of showing some degree of recovery in their platelet count (at least to a level greater than 20x10^9/l) 
in the short term. Conversely, a patient with an IPF of less than 6% has a 70% chance of showing no 
imminent improvement in their platelet count.   
Of interest was the finding in 13 patients whose platelet counts had dropped over the course of 
follow-up, nearly half of whom had a high IPF. The latter finding is likely to reflect the presence of 
unchecked peripheral mechanisms causing the thrombocytopenia. Indeed, upon review of the clinical 
presentations of these patients, three of the six were found to have splenomegaly. Therefore, 
because splenomegaly is fairly unlikely to recede rapidly, the effects of hypersplenism are likely to 
persist for some time. In keeping with this surmise, is the fact that of the 7 patients in the cohort with 
splenomegaly and a follow-up platelet count, only 1 had a satisfactory improvement in the platelet 
count over the brief follow-up period.   
4.5.2 Platelet count response among patient sub-groups:  
Among the patient sub-groups, it is interesting to note that patients on ARVs showed significantly 
better platelet count responses than those not on ARVs, despite having very similar mean platelet 
counts and distribution of pathologies (see Table 3.5 and Figure 3.12). In fact, the relationship 
between ARV therapy and platelet count recovery was stronger than the association between CD4 
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count and the platelet count response. This finding would suggest that ARV therapy enables more 
rapid recovery from the underlying mechanism causing the thrombocytopenia in a manner 
independent of CD4 count. Because ARV therapy would be expected to reduce the viral load, the 
beneficial effects observed may be a consequence of reduced megakaryocyte suppression as caused 
by the virus per se, which may then produce a better degree of megakaryocyte fitness in this patient 
group. This hypothesis is supported by the apparently better platelet count response in patients with 
low viral loads (i.e. <10 000 copies per ml) as compared to those with higher viral loads. 
Unfortunately, the latter finding did not reach statistical significance (p=0.1), as a result of the very 
small number of patients with both a viral load result and a follow-up platelet count available (N=13).  
 
Lastly, the absence of any relationship between the short term platelet response and the presence of 
megakaryocyte disorder is of interest, and suggests that the morphological characteristics of 
megakaryopoiesis are a poor reflection of megakaryocyte fitness. 
 
4.6 Case studies illustrating some of the strengths and limitations of 
the IPF parameter: 
In this cohort, four patients had extensive marrow infiltration by malignancies, and would therefore 
be intuitively expected to have centrally mediated thrombocytopenia. However, the IPF was 
unexpectedly found to be elevated in three of these patients. The IPF is measured as a proportion of 
the optical fluorescent platelet count. The latter utilizes a complex mathematical algorithm 
combining both the size of a cell and its fluorescent characteristics to decide its cellular nature [57]. 
This prevents non-cellular debris from being counted as platelets, and giant platelets from being 
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counted as red cells. However, it has been shown that the optical platelet count as measured on 
Sysmex instruments may be inaccurate in patients receiving cytotoxic chemotherapy, which is 
thought to be a consequence of circulating fragments of apoptotic white blood cells being 
erroneously counted as platelets by the analyzer [58].  Therefore, it would be logical to expect the IPF 
to become unreliable in any instance in which the optical platelet count cannot be trusted. In 
addition, as white blood cell cytoplasm is rich in RNA, a spurious elevation of the IPF would be 
anticipated. 
 
 Of the three patients with a high IPF despite extensive marrow infiltration, two  had large B-cell 
lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and 
Burkitt lymphoma, with platelet counts of 5x10^9/l and 18x10^9/l, and IPFs of 7,8% and 8,8% 
respectively.  As large B-cell lymphoma unclassifiable with features intermediate between diffuse 
large B-cell lymphoma and Burkitt lymphoma  is a pathology associated with a high proliferative index 
and a brisk rate of tumour apoptosis [59], it is possible that the mildly elevated IPF levels in these 
cases occurred spuriously as a result of the presence of circulating fragments of apoptotic tumour 
cells, despite the absence of a history of chemotherapy exposure. The third example occurred in a 34 
year old female patient with extensive marrow infiltration by metastatic carcinoma of the breast. The 
patient presented with a severe thrombocytopenia (platelets=6x10^9/l), and was initiated on both 
tamoxifen and corticosteroids before the bone marrow investigation was performed, at which time 
the IPF was found to be 15%. In view of the history of chemotherapy exposure, it seems likely that 
this IPF level should be treated with a degree of circumspection. However, as the IPF level was 
significantly elevated, the possibility remains that the pathology observed in the bone marrow 
sample was only focal, and that a peripheral pathology was present concurrently. This consideration 
is partially supported by the fact that the platelet count showed a good recovery in response to the 
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treatment instituted, (which included an immunosuppressive agent), rising to a level of 75x10^9/l 
over the next 7 days. This could reflect the presence of an associated immune-mediated process. 
Therefore, although the precise mechanism of thrombocytopenia remains obscure in this particular 
case, this example highlights one of the most compelling potential merits of the IPF in its ability to 
reflect global megakaryopoiesis, while a bone marrow specimen is only focally representative.  
 
The latter example illustrates the potential value of an elevated IPF in detecting the presence of 
peripherally mediated thrombocytopenia. However, it must be remembered that the converse is not 
universally true, particularly amongst a patient population in whom multiple mechanisms may occur 
concurrently. In other words, the presence of a low IPF does not exclude a peripheral contributor to 
the thrombocytopenia. This is clearly illustrated in two cases of interest. The first, a 23 year old male 
patient who presented with a platelet count of 35x10^9/l and an IPF of 5.8%. His clinical and 
morphological features were suggestive of a diagnosis of ITP, and he responded very well to steroid 
therapy. However, at the time of his presentation, he was also iron deficient as a consequence of 
chronic blood loss (which was presumed to be a product of long standing thrombocytopenia). As iron 
is necessary for megakaryopoiesis [60], it is likely that his thrombocytopenia was a product of both 
immune mediated platelet destruction and iron depletion, while the low IPF level reflected only the 
dominant mechanism at play (i.e. iron deficiency in this case).  
The second case of interest is one of the cases of TTP. The patient presented with a platelet count of 
18x10^9/l, and had an unexpectedly low IPF of 4.5%. However, this platelet count was measured by 
optical fluorescence, and review of the peripheral slide revealed a severely reduced platelet count 
(more compatible with the impedence-based platelet count in this case, which was 7x10^9/l) (see 
Figure 3.10).  The discrepancy between the visually assessed platelet count and the optical platelet 
count suggests that non-platelet structures have been designated as platelets by the instrument. In 
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this instance, these non-platelet structures are likely to have been small red cell fragments, (which 
were present in large numbers), a hypothesis which is supported by the failure of the analyzer to flag 
their presence. As discussed above, the IPF becomes unreliable when the optical platelet count is in 
doubt. Although this does not appear to be a common problem, (as no similar cases have been 
reported in the literature [45, 61]), a low IPF should perhaps be treated with a degree of caution in 
the setting of severe red cell fragmentation.  
 
Finally, as an indirect reflector of good marrow megakaryocyte activity, the presence of a high IPF has 
been proposed to allow for the omission of a bone marrow investigation in certain clinical scenarios 
[45].  However, the wide variation in IPF levels among patients with frank marrow pathology in this 
cohort render this possibility untenable in the setting of HIV-associated thrombocytopenia, even 
when the clinical presentation is strongly suggestive of a peripherally driven pathogenic process. This 
is clearly demonstrated in the case of a 27 year old male patient who presented with clinical features 
strongly suggestive of a diagnosis of ITP and an IPF of 17%. His bone marrow aspirate showed very 
brisk megakaryopoietic activity, and he responded well to steroid therapy. However, examination of 
his trephine biopsy revealed the unexpected presence of a peripheral T-cell lymphoma. In 
conjunction with the presence of an elevated IPF in over 40% of the patients with evidence of 
mycobacterial infection in their bone marrow and in three quarters of the patients with extensive 
marrow infiltration by malignancy, omission of a bone marrow investigation in the setting of HIV-
associated thrombocytopenia would clearly be ill advised, regardless of the IPF level.  
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Chapter 5 
5.0 Conclusion 
Thrombocytopenia in the setting of HIV has many potential aetiologies, and the exact nature of the 
pathophysiological mechanism at play is often not easily determined by morphological examination 
of the bone marrow.  In this study it has been shown that the IPF level correlates well with the bone 
marrow findings in HIV positive patients when the cause of thrombocytopenia is readily apparent on 
clinical and morphological grounds (as is the case in patients with ITP/TTP or hypocellular marrow). 
The IPF is therefore assumed to be a fair reflector of the predominant mechanism at play when the 
underlying pathophysiological process is more obscure, with a high IPF suggesting the presence of 
peripherally-driven thrombocytopenia, and a low IPF being a consequence of inadequate 
megakaryocytic activity.   Based on this premise, the findings of this study suggest that, in the context 
of AIDS, severe thrombocytopenia is significantly more frequently a consequence of peripheral 
mechanisms, while mild thrombocytopenia is more often a product of a depressed bone marrow 
response.   That being said, the underlying mechanism resulting in thrombocytopenia is very 
heterogeneous in individuals with AIDS, even among patients with a uniform histological diagnosis 
(such as bone marrow infiltration by TB). 
 
Furthermore, there is a very poor correlation between the morphological characteristics of 
megakaryopoiesis (including absolute megakaryocyte numbers as well as the presence or absence of 
varying degrees of megakaryocyte dysplasia) with the true effectiveness of thrombopoiesis (as 
manifest as an elevation in the IPF level). The IPF is therefore a potentially useful tool to assist the 
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pathologist in interpreting the morphological features in HIV-positive patients with 
thrombocytopenia.  
IPF levels greater than 10% or less than 6% have good specificity and positive predictive values for 
predicting the presence and absence respectively of a clinically meaningful improvement in the 
platelet count over the short-term.  
In addition, this study has also illuminated some of the limitations of the IPF parameter, particularly 
in any instance in which the optically measured platelet count is in doubt. This includes some patients 
with extensive marrow infiltration by malignancy as well as some patients with severe red cell 
fragmentation. 
Lastly, some of the characteristics of HIV related thrombocytopenia have been clarified in this study, 
particularly with respect to the effects of ARV therapy. It was found that although the patients on 
ARVs included had similar spectra of pathologies and mean CD4 counts as compared to patients not 
on ARVs, those with evidence of good virological control were significantly less likely to develop 
severe thrombocytopenia, and  more likely to show an improvement in their platelet count over the 
short term. Because these effects were seen most pronouncedly among patients who had evidence 
of good virological suppression without significant immunological recovery,   HIV itself is implicated 
as a very important modifier of thrombopoiesis. Although it is well known that HIV per se has effects 
on megakaryopoiesis, (particularly as a result of direct viral infection of megakaryocytes [20]), the 
findings of this study indirectly illuminate the effects of that infection on megakaryocyte fitness.  
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